Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective

Clinical Pharmacokinetics

Volumn 32, Issue 4, 1997, Pages 294-312

  Samara, Emil ^a   Granneman, Richard ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD SAMPLING; CANCER; CLINICAL STUDY; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; PHARMACOKINETICS; POPULATION; PRIORITY JOURNAL; REVIEW;

EID: 0030931325     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732040-00003     Document Type: Review

References (133)

1. Gerhard L, Ebling We, Forrest A. Concentration or effect-controlled clinical trials with sparse data. Clin Pharmacol Ther 1994; 56 (1): 1-8
2. Temple R. Discussion paper on the testing of drugs in the elderly. Washington, DC: Memorandum of the Food and Drug Administration of DHHS, 1983 Sep 30
3. Sheiner LB, Benet LZ. Premarketing observational studies of population pharmacokinetics of new drugs. Clin Pharmacol Ther 1985; 38 (5): 481-7
4. Aarons L, Balant LP, Mentre F, et al. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol 1996; 49: 251-4
5. Aarons L, Balant LP, Mentre F, et al. Population approach in drug development. Eur J Clin Pharmacol 1994; 46: 389-91
6. Steimer JL, Vozeh S, Racine-Poon A, et al. The population approach: rationale, methods, and applications in clinical pharmacology and drug development. In: Welling PE, Balant LP, editors. Handbook of experimental pharmacology, Vol. 110. Pharmacokinetics of drugs. Heidelberg: Springer-Verlag, 1994: 405-51
7. Ludden TM. Population pharmacokinetics. J Clin Pharmacol 1988; 28: 1059-63
8. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics: theory and clinical application. Clin Pharmacokinet 1986; 11: 387-401
9. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992; 32: 185-209
10. Whiting B. The population approach: applications to date. An overview. In: Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities, 1992: 41-56
11. Peck CC. Population approach in pharmacokinetics and pharmacodynamics: FDA view. In: Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities, 1992: 157-68
12. Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Pharm Res 1992; 9 (6): 826-33
13. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comp Biomed Res 1972; 5: 441-59
14. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5 (5): 445-79
15. Mentre F, Gomeni R. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J Biopharm Stat 1995; 5 (2): 141-58
16. Kisor DF, Watling SM, Zarowitz BJ, et al. Population pharmacokinetics of gentamicin: use of the nonparametric expectation maximisation (NPEM) algorithm. Clin Pharmacokinet 1992; 23 (1): 62-8
17. Mentre F, Mallet A. Experiences with NPML: application to dosage individualization of cyclosporine, gentamicin and zidovudine. In: Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities, 1992: 75-89
18. Best NG, Tan KKC, Gilks WR, et al. Estimation of population pharmacokinetics using the gibbs sampler. J Pharmacokinet Biopharm 1995; 23 (4): 407-35
19. Laplanche R, Fertil B, Nuesch E, et al. Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine. Clin Pharmacol Ther 1991; 50: 39-54
20. Grevel J, Post BK, Kahan BD, Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients. Clin Pharmacol Ther 1993; 53: 651-60
21. Awni WM, Granneman GR, Locke CS, et al. Population pharmacokinetics of zileuton, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1995; 48 (2): 155-60
22. Gitterman SR, Drusano GL, Egorin MJ, et al. Population pharmacokinetics of zidovudine. Clin Pharmacol Ther 1990; 48: 161-7
23. Samara E, Lam S-Y, Ludden T. Population pharmacokinetics of a third generation cephalosporin in a pediatric population [abstract]. Pharmacol Res 1992; 9: 311
24. Chatelut E, Boody AV, Peng B, et al. Population pharmacokinetcis of carboplatin in children. Clin Pharmacol Ther 1996; 59: 436-43
25. Collart L, Blaschke TF, Boucher F, et al. Polential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Dev Pharmacol Ther 1992; 18 (1-2): 71-80
26. Yukawa E, Mine H, Higuchi S, et al. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol 1992; 44: 761-5
27. Yuen GJ, Drusano GL, Brooks J, et al. Use of nonlinear, mixed effect modeling for population analysis of ofloxacin: effects of age on oral drug pharmacokinetics. Pharmacotherapy 1992; 12: 88-92
28. Sabot C, Debord J, Roullet B, et al. Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics. Inter J Clin Pharmacol Ther 1995; 32: 164-9
29. Pai SM, Shukla UA, Grasela TH, et al. Population pharmacokinetic analysis of didanosine (2′,3′-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex. J Clin Pharmacol 1992; 32: 242-7
30. Tod M, Pobel C, Le Gros V, et al. A population pharmacokinetic study of alminoprofen penetration into synovial fluid. Biopharm Drug Dispos 1995 Nov; 16: 627-34
31. Debord J, Pessis C, Voultoury JC, et al. Population pharmacokinetics of amikacin in intensive care unit patients studied by NPEM algorithm. Fundam Clin Pharmacol 1995; 9 (1): 57-61
32. Amantea MA, Bowden RA, Forrest A, et al. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother 1995; 39: 2042-7
33. Neef C, Jelliffe RW, van Laar T, et al. Population pharmacokinetics of apomorphine in patients with Parkinson's disease. Drug Invest 1994; 7: 183-90
34. Uematsu T. Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug. Int J Clin Pharmacol Ther Toxicol 1993; 31: 606-10
35. Martin ES, Crismon ML, Godley PJ. Postinduction carbamazepine clearance in an adult psychiatric population. Pharmacotherapy 1991; 11: 296-302
36. Yukawa E. Population-based investigation of carbamazepine relative clearance using routine clinical pharmacokinetic data in Japan: a multiple peak approach feasibility study for pharmacokinetic screening. Clin Drug Invest 1995; 10: 29-39
37. Chatelut L, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573-80
38. Piotrovskij VK, Gajdos M, Illek B, et al. Application of a population pharmacokinetic modeling to bioavailability/bioequivalence study of cefadroxil preparations. Int J Pharm 1995; 119: 213-21
39. Forrest A, Ballow CH, Nix DB, et al. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993; 37: 1065-72
40. Launay-Iliadis MC, Bruno R, Cosson V, et al. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 1995; 37: 47-54
41. Bressolle F, Ray P, Jacquet JM, et al. Bayesian estimation of doxorubicin pharmacokinetic parameters. Cancer Chemother Pharmacol 1991; 29: 53-60
42. Wade JR, Kelman AW, Kerr DJ, et al. Variability in pharmacokinetics of epirubucin: a population analysis. Cancer Chemother Pharmacol 1992; 29: 391-5
43. Aarons L. The kinetics of flurbiprofen in synovial fluid. J Pharmacokinet Biopharm 1991; 19 Suppl.: 265-9
44. Yuen GJ, Drusano GL, Fletcher C, et al. Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. Antimicrob Agents Chemother 1995; 39: 2350-2
45. Jhee SS, Burm JP, Gill MA. Comparison of aminoglycoside pharmacokinetics in asian, hispanic, and caucasian patients by using population pharmacokinetic methods. Antimicrob Agents Chemother 1994; 38 (9): 2073-7
46. Watling SM, Kisor DF. Population pharmacokinetics: development of a medical intensive care unit-specific gentamicin dosing nomogram. Ann Pharmacother 1993; 27: 151-4
47. Tracewell WG, Trump DL, Vaughan WP, et al. Population pharmacokinetics of hydroxyurea in cancer patients. Cancer Chemother Pharmacol 1995; 35: 417-22
48. Olson SC. A population pharmacokinetic profile of imazodan in congestive heart failure patients. J Pharmacokinet Biopharm 1991; 19 Suppl.: 47-58
49. Antal EJ, Grasela Jr TH, Ereshefsky L, et al. A multi-center study to evaluate the pharmacokinetic and clinical interactions between alprazolam and imipramine. J Pharmacokinet Biopharm 1991; 19 Suppl.: 93-100
50. Tanigawara Y, Nomura H, Kagimoto N, et al. Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Biol Pharm Bull 1995; 18: 315-20
51. Jermain DM, Crismon ML, Martin III ES. Population pharmacokinetics of lithium. Clin Pharm 1991; 10: 376-81
52. Taright N, Mentre F, Mallet A, et al. Nonparametric estimation of population characteristics of the kinetics of lithium from observational and experimental data: individualization of chronic dosing regimen using a new Bayesian approach. Ther Drug Monit 1994; 16: 258-69
53. Yukawa E, Nomiyama N, Higuchi S, et al. Lithium population pharmacokinetics from routine clinical data: role of patients characteristics for estimating dosing regimens. Ther Drug Monit 1993; 15: 75-82
54. Maitre PO, Buhrer M, Thomson D, et al. A three-slop approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 1991; 19: 377-84
55. Jerling M, Merle Y, Mentre F, et al. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6: an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1944; 38: 453-62
56. Mandema WJ, Kaiko FR, Oshlack B, et al. Characterization and validation of a pharmacokinetic model for controlled-rclease oxocodone. Br J Clin Pharmacol 1996; 42: 747-56
57. Bruno R, Iliadis MC, Lacarelle B, et al. Evaluation of Bayesian estimation in comparison 10 NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. J Pharmacokinet Biopharm 1992; 20: 653-69
58. Fabre D, Bressolle F, Gomeni R, et al. Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters. Clin Pharmacokinet 1993; 24: 333-43
59. Yukawa E, Higuchi S, Aoyama T. Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol 1992; 44: 755-60
60. Chan E, Ti TY, Lee HS. Population pharmacokinetics of phenytoin in Singapore Chinese. Eur J Clin Pharmacol 1990; 39: 177-81
61. Yukawa E, Higuchi S, Aoyama T. One-point feedback control method for phenytoin dosage adjustment. J Pharm Pharmacol 1991; 43: 499-503
62. Samara E, Cavanaugh JH, Mukherjee D, et al. Lack of pharmacokinetic interaction between zileuton and phenytoin in humans. Clin Pharmacokinet 1995; 29 Suppl. 2: 84-91
63. Fattinger K, Vozeh S, Ha HR, et al. Population pharmacokinetics of quinidine. Br J Clin Pharmacol 1991; 31: 279-86
64. Verme CN, Ludden TM, Clementi WA, et al. Pharmacokinetics of quinidine in male patients: a population analysis. Clin Pharmacokinet 1992; 22: 468-80
65. Egan TD, Lemmens HJM, Fiset P, et al. The pharmacokinetics of new short acting opoid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 1993; 79: 881-92
66. Kleinbloesem CH, Weber C, Fahrner E, et al. Hemodynamics, biochemical effects and pharmacokinetics of renin inhibitor remikiren in healthy human subjects. Clin Pharmacol Ther 1993; 53: 585-92
67. 2 receptor antagonist (AA-2414) in normal subjects: population analysis. Clin Pharmacol Ther 1994; 55 (4): 441-50
68. Horton CM, Dudley MN, Kaul S, et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 1995; 39: 2309-15
69. Jodrell DI, Reyno LM, Sridhara R, et al. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentrations in patients with prostate cancer. J Clin Oncol 1994; 12: 166-75
70. Thomas G, Koen R, Houze P, et al. Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients. Fundam Clin Pharmacol 1991; 5 (7): 611-9
71. Yano I, Tanigawara Y, Yasuhara M, et al. Population pharmacokinetics of theophylline II: intravenous infusion to patients with stable chronic airway obstruction. Biol Pharm Bull 1993; 16: 501-5
72. Stanski DR, Maitre PO. Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited. Anesthesiology 1990; 72: 412-22
73. Grasela TH, Fiedler-Kelly JB, Salvadori C, et al. Development of a population pharmacokinetic database for tianeptine. Eur J Clin Pharmacol 1993; 45 (2): 173-9
74. Yu DK, Hutcheson SJ, Wei G, et al. A comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data. Biopharrn Drug Dispos 1994; 15: 473-84
75. Pitsiu M, Parker EM, Aarons L, et al. Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults. Eur J Pharm Sci 1993; 1: 151-7
76. Bachman WJ, De Lap RJ. Population pharmacokinetics of high-dose zidovudine in a phase I cancer study. Drug Invest 1994; 8: 134-42
77. Hashimoto Y, Odani A, Tanigawara Y, et al. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull 1994; 17: 323-6
78. Izquierdo M, Lanao JM, Cervero L, et al. A comparative study of the population pharmacokinetics of gentamicin and amikacin in newborn patients. J Clin Pharm Ther 1993; 18: 411-3
79. Peng B, Boddy AV, Cole M, et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer (Part A) 1995; 31A: 1804-10
80. Karna P, Lee C, Kumar A. Population pharmacokinetics of ceftizoxime in premature newborns. Dev Pharmacol Ther 1993; 20 (3-4): 135-43
81. Izquierdo M, Lanao KM, Cervero L, et al. Population pharmacokinetics of gentamicin in premature infants. Ther Drug Monit 1992; 14: 177-83
82. Jensen PD, Edgren BE, Brundage RC. Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed effect model. Pharmacotherapy 1992; 12 (3): 178-82
83. Dodge WF, Jelliffe RW, Richardson CJ, et al. Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. Clin Pharmacol Ther 1991; 50: 25-31
84. Weber W, Kewitz G, Rost KL, et al. Population kinetics of gentamicin in neonates. Eur J Clin Pharmacol 1993; 44 Suppl. 1: 23-5
85. Dodge WF, Jelliffe RW, Zwischenberger JB, et al. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit 1994; 16: 552-9
86. Tamayo M, Fernandez de Gatta MM, Garcia MJ, et al. Population pharmacokinetics of imipramine in children. Eur J Clin Pharmacol 1992; 43: 89-92
87. Wiest DB, Pinson JB, Gal PS, et al. Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus. Clin Pharmacol Ther 1991; 49: 550-7
88. Parker EM, Hutchison M, Blumer JL. The pharmacokinetics of meropenem in infants and children: a population analysis. J Antimicrob Chemother 1995; 36 Suppl. A: 63-71
89. Burtin P, Jacqz-Aigrain E, Girard P, et al. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther 1994; 56: 615-25
90. Fattinger K, Vozeh S, Olafsson A, et al. Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations. Clin Pharmacol Ther 1991; 50: 55-65
91. Botha JH, Gray AL, Miller R. Determination of phenobarbitone population clearance values for South African children. Eur J Clin Pharmacol 1995; 48 (5): 381-3
92. Kataria BK, Ved SA, Nicodemus HF, et al. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology 1994; 80: 104-22
93. Yano I, Tanigawara Y, Yasuhara M, et al. Population pharmacokinetics of theophylline. I. Intravenous infusion to children in the acute episode of asthma. Biol Pharm Bull 1993; 16: 59-62
94. Botha JH, Tyrannes I, Miller R, et al. Determination of theophylline clearance in South African children. Eur J Clin Pharmacol 1993; 44 (4): 369-75
95. Martin III ES. The population pharmacokinetics of theophylline during the early postnatal period. J Pharmacokinet Biopharm 1991; 19 Suppl.: 59-77
96. Karlsson MO, Thomson AH, McGovern EM, et al. Population pharmacokinetics of rectal theophylline in neonates. Ther Drug Monit 1991; 13: 195-200
97. Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 1994; 56: 169-75
98. Grasela TH, Antal EJ, Ereshefsky L, et al. An evaluation of population pharmacokinetics in therapeutic trials: Pt II. Detection of a drug-drug interaction. Clin Pharmacol Ther 1987; 42: 433-41
99. Williams PJ, Lane J, Murray W, et al. Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling. Clin Pharmacokinet 1992; 22 (1): 66-74
100. Tanigawara Y, Hori R. Population approach in post-marketing dose adjustment. In: Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities, 1992: 223-32
101. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993, 21: 735-50
102. Steimer JL, Ebelin ME, Van Bree J. Pharmacokinetic and pharmacodynamic data and models in clinical trials. Eur J Drug Metab Pharmacokinet 1993; 18: 61-7
103. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9 (6): 739-56
104. Ette EI, Kelman AW, Howie CA, et al. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters. Ann Pharmacother 1993; 27: 1034-9
105. Al-Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm 1990; 18: 347-60
106. Ette EI, Sun H, Ludden TM. Design of population pharmacokinetic studies. Proc Am Stat Assoc 1994: 487-92
107. Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996; 30 (2): 81-93
108. Beal SL, Sheiner LB. NONMEM user's guide. NONMEM Project Group, University of California San Francisco, 1992
109. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate analysis. J Pharmacokinet Biopharm 1992; 20: 511-28
110. Ette EI, Ludden TM. Population pharmacokinetic modelling: the importance of informative graphics. Pharm Res 1995; 12 (12): 1845-55
111. Vozeh S. Applications of population approach to clinical pharmacokinetics and validation of the results. In: Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities, 1992: 107-20
112. Hollord NHG, Peace KE. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 1992; 89: 11471-5
113. Elle EI, Kelman AW, Howie CA, et al. Influence of inter-animal variability on the estimation of population pharmacokinetic parameters in preclinical studies. Clin Res Reg Affairs 1994; 11 (2): 121-39
114. Ette EI, Howie CA, Kelman AW, et al. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies. Pharm Res 1995; 12 (5): 729-37
115. Mentre F, Burtin P, Merle Y, et al. Sparse-sampling optimal designs in pharmacokinetics and toxicokinetics. Drug Inf J 1995; 29: 997-1019
116. Van Bree J, Nedelman J, Steimer JL, et al. Application of sparse sampling approaches in rodent toxicokinetics: a prospective view. Drug Inf J 1994; 28: 263-79
117. Aarons L, Mandema JW, Danhof M. A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat. J Pharmacokinet Biopharm 1991; 19 (5): 485-96
118. Troconiz IF, Lopez-Bustamante LG, Fos D. Tenoxicam pharmacokinetics in rats: a population model. J Pharm Sci 1995; 84 (12): 1482-7
119. Ette EI, Kelman AW, Howie CA, et al. An application of the population approach to animal pharmacokinetics during drug development. Clin Res Reg Affairs 1994; 11 (3-4): 243-55
120. Li Z, Chen G, Zhuo HT. Application of NONMEN method to evaluation of relative biological availability of ofloxacin. Acta Pharmacol Sinica 1994; 15: 39-42
121. Graves DA, Chang I. Application of NONMEM to routine bioavailability data. J Pharmacokinet Biopharm 1990; 18 (2): 145-60
122. Kaniwa N, Aoyagi N, Ogata H, et al. Application of the NONMEM method to evaluation of the bioavailability of drug products. J Pharm Sci 1990; 79: 1116-20
123. Samara E, Granneman R, Locke CS, et al. Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with moderate asthma. Clin Pharmacol Ther 1996; 59 (2): 208
124. Toon S. Relevance of pharmacokinetic studies in volunteers. Clin Pharmacokinet 1993; 25 (4): 259-62
125. Crome P, Flanagan RJ. Pharmacokinetic studies in elderly people: are they necessary? Clin Pharmacokinet 1994; 26 (4): 243-7
126. Narang PK, Sale M. Population based assessment of rifabutin effect on zidovudine disposition in AIDS patients. Clin Pharmacol Ther 1993; 53 (2): 219
127. Holford NHG, Williams PEO, Muirhead GJ, et al. Population pharmacodynamic of romazarit. Br J Clin Pharmacol 1995; 39: 313-20
128. Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60: 619-35
129. Holford NHG, Peace KE. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Sci USA 1992; 89: 11466-70
130. Guentert TW, Banken L, Hilton S, et al. Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. J Clin Psychopharmacol; 15 (4 Suppl. 2): 84S-93S
131. Holford N, Hashimoto Y, Sheiner LB. Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction: population analysis of a randomised concentration controlled trial. Clin Pharmacokinet 1993; 25: 506-15
132. Grasela TH, Fiedler-Kelly JB, Salvadori C, et al. Predictive performance of population pharmacokinetic parameters of tianeptine as applied to plasma concentrations from a post-marketing study. Eur J Clin Pharmacol 1993; 45: 123-8
133. DeVane CL, Grasela TH, Antal EJ, et al. Evaluation of population pharmacokinetics in therapeutic trials: IV. Application to postmarketing surveillance. Clin Pharmacol Ther 1993; 53 (5): 521-8